Skip to content

Study on the Effects of Bifidobacterium longum and Dietary Factors Combination on Protein-Bound Toxins and Intestinal Flora in Hemodialysis Patients

Study on the Effects of Bifidobacterium longum and Dietary Factors Combination on Protein-Bound Toxins and Intestinal Flora in Hemodialysis Patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108409
Enrollment
Unknown
Registered
2025-08-29
Start date
2025-08-31
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD5?MHD

Interventions

control group:NA
Dietary factor group:Dietary factor
probiotic + dietary factor group:probiotics+Dietary factors

Sponsors

Wuxi people’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Have received maintenance hemodialysis treatment for more than 3 months; 2.Age: 18-80 years old, gender not limited; 3.Willing to participate after full informed consent.

Exclusion criteria

Exclusion criteria: 1.Antibiotics have been used within one month before enrollment; 2.Taking immunosuppressants, foods or drugs containing probiotics or prebiotic substances at the same time; 3.The primary diseases are systemic lupus erythematosus, vasculitis, autoimmune diseases and those combined with malignant tumors, end-stage liver diseases, and chronic intestinal diseases; 4.Gastrointestinal diseases, including irritable bowel syndrome, Crohn's disease or ulcerative colitis; 5.Pregnant or lactating women. (5) Patients who have been bedridden for a long time are unable to eat by themselves; 6.Patients with combined mental disorders that affect treatment compliance; 7.Unable, unwilling or unwilling to comply with the research requirements, including lifestyle adjustments, follow-up visits and subject responsibilities; 8.Patients with a history of kidney transplantation or those planning to undergo kidney transplantation within six months; 9.Allergy or intolerance to the ingredients of the experimental probiotic product; 10.Patients who are simultaneously undergoing other clinical trials.

Design outcomes

Primary

MeasureTime frame
Serum protein-binding toxoids;

Secondary

MeasureTime frame
Inflammatory factors;

Countries

China

Contacts

Public Contactzhijianzhang

Wuxi people’s Hospital

zzjwxyy@163.com+86 510 8535 1161

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026